Angiotensin I (human, mouse, rat)

Product Name:Angiotensin I (human, mouse, rat)

CAS No:484-42-4

Purity:95%

Molar Mass:1296.5

Chemical Formula:C62H89N17O14

Storage:Store at -20 degrees Celsius

Sequence:DRVYIHPFHL

Application:

Angiotensin I is a decapeptide that plays a critical role in the renin-angiotensin system (RAS), which regulates blood pressure, fluid balance, and electrolyte homeostasis across various species, including humans, mice, and rats. This peptide is an inactive precursor that is converted by the angiotensin-converting enzyme (ACE) into angiotensin II, a potent vasoconstrictor. Angiotensin I is extensively used in cardiovascular research to study the mechanisms of hypertension, heart failure, and kidney function. The peptide's conservation across species makes it a valuable tool for comparative studies in different animal models, aiding in the understanding of RAS-related diseases and the development of therapeutic interventions targeting this pathway.

Current Research:

Angiotensin I is a decapeptide precursor in the renin-angiotensin system (RAS), playing a pivotal role in blood pressure regulation and fluid homeostasis across human, mouse, and rat species. Generated by the cleavage of angiotensinogen by renin, it is subsequently converted to the active peptide angiotensin II by angiotensin-converting enzyme (ACE). While angiotensin I itself is inactive, its conversion and interaction with downstream effectors highlight its importance in cardiovascular and renal physiology.
Research Applications:
Angiotensin I serves as a critical substrate in studies exploring the enzymatic activity of ACE and the pharmacodynamics of ACE inhibitors. By utilizing angiotensin I from human, mouse, or rat origins, researchers can investigate species-specific variations in RAS functionality, which is crucial for translational studies. Moreover, angiotensin I is employed in models studying hypertension, cardiac remodeling, and renal disease.
Drug Discovery Potential:
The availability of angiotensin I peptides from multiple species enables comparative analyses of RAS-targeted therapies, aiding in the development of novel antihypertensive agents. Understanding the kinetics of angiotensin I conversion to angiotensin II in different species also supports the design of ACE inhibitors with improved specificity and efficacy. Additionally, angiotensin I is instrumental in the characterization of RAS-modulating drugs, including angiotensin receptor blockers (ARBs) and direct renin inhibitors.
Conclusion:
Angiotensin I remains an indispensable tool in RAS-related research, providing foundational insights into cardiovascular and renal pathophysiology. Its application in preclinical and translational research underscores its value in advancing therapeutic interventions for hypertension and related disorders. Ongoing studies leveraging angiotensin I will continue to refine our understanding of RAS and its therapeutic potential.

Reference:

Gonzalez-Villalobos, R. A., Satou, R., Ohashi, N., Semprun-Prieto, L. C., Katsurada, A., Kim, C., ... & Navar, L. G. (2010). Intrarenal mouse renin-angiotensin system during ANG II-induced hypertension and ACE inhibition. American Journal of Physiology-Renal Physiology, 298(1), F150-F157.